Cue Biopharma, Inc. (CUE)
CUE Stock Price Chart
Explore Cue Biopharma, Inc. interactive price chart. Choose custom timeframes to analyze CUE price movements and trends.
CUE Company Profile
Discover essential business fundamentals and corporate details for Cue Biopharma, Inc. (CUE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Jan 2018
Employees
41.00
Website
https://www.cuebiopharma.comCEO
Lucinda Warren
Description
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.
CUE Financial Timeline
Browse a chronological timeline of Cue Biopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Aug 2026
EPS estimate is -$1.69, while revenue estimate is $3.00m.
Earnings released on 14 May 2026
EPS came in at -$1.08 surpassing the estimated -$3.30 by +67.27%, while revenue for the quarter reached $5.69m , beating expectations by +127.44%.
Stock split effective on 24 Apr 2026
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 Mar 2026
EPS came in at $0.30 surpassing the estimated -$2.70 by +111.11%, while revenue for the quarter reached $21.94m , beating expectations by +2.09k%.
Earnings released on 12 Nov 2025
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%, while revenue for the quarter reached $2.15m , missing expectations by -6.14%.
Earnings released on 12 Aug 2025
EPS came in at -$0.09 surpassing the estimated -$0.13 by +30.77%, while revenue for the quarter reached $2.95m , beating expectations by +47.70%.
Earnings released on 12 May 2025
EPS came in at -$0.17 falling short of the estimated -$0.14 by -21.43%, while revenue for the quarter reached $421.00k , missing expectations by -66.79%.
Earnings released on 31 Mar 2025
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $1.58m , missing expectations by -7.36%.
Earnings released on 14 Nov 2024
EPS came in at -$0.17 surpassing the estimated -$0.20 by +15.00%, while revenue for the quarter reached $3.34m , beating expectations by +119.55%.
Earnings released on 19 Aug 2024
EPS came in at -$0.20 surpassing the estimated -$0.29 by +31.03%, while revenue for the quarter reached $2.66m , beating expectations by +106.21%.
Earnings released on 9 May 2024
EPS came in at -$0.25 surpassing the estimated -$0.30 by +16.67%, while revenue for the quarter reached $1.72m , beating expectations by +41.83%.
Earnings released on 8 Apr 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%, while revenue for the quarter reached $1.82m , beating expectations by +88.38%.
Earnings released on 9 Nov 2023
EPS came in at -$0.24 surpassing the estimated -$0.30 by +20.00%, while revenue for the quarter reached $2.10m , beating expectations by +60.61%.
Earnings released on 9 Aug 2023
EPS came in at -$0.29 surpassing the estimated -$0.30 by +3.33%, while revenue for the quarter reached $1.38m , beating expectations by +52.29%.
Earnings released on 9 May 2023
EPS came in at -$0.29 surpassing the estimated -$0.33 by +12.12%, while revenue for the quarter reached $187.00k , missing expectations by -90.41%.
Earnings released on 21 Mar 2023
EPS came in at -$0.37 falling short of the estimated -$0.32 by -15.62%, while revenue for the quarter reached $151.00k , beating expectations by +45.54%.
Earnings released on 14 Nov 2022
EPS came in at -$0.31 surpassing the estimated -$0.38 by +18.42%, while revenue for the quarter reached $68.00k , missing expectations by -86.76%.
Earnings released on 4 Aug 2022
EPS came in at -$0.37 surpassing the estimated -$0.42 by +11.90%, while revenue for the quarter reached $26.00k , missing expectations by -97.70%.
Earnings released on 10 May 2022
EPS came in at -$0.44 falling short of the estimated -$0.43 by -2.33%, while revenue for the quarter reached $1.00m , missing expectations by -67.26%.
Earnings released on 16 Mar 2022
EPS came in at -$0.26 surpassing the estimated -$0.42 by +38.39%, while revenue for the quarter reached $8.25m , beating expectations by +624.67%.
Earnings released on 9 Nov 2021
EPS came in at -$0.41 falling short of the estimated -$0.39 by -5.13%, while revenue for the quarter reached $2.40m , beating expectations by +16.83%.
Earnings released on 9 Aug 2021
EPS came in at -$9.91 falling short of the estimated -$0.42 by -2.26k%, while revenue for the quarter reached $2.74m , meeting expectations.
CUE Stock Performance
Access detailed CUE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
